AL-S Pharma has released new data from the phase 2 trial evaluating its drug AP-101 in patients with amyotrophic lateral sclerosis (ALS). ALS is a progressive neurodegenerative disease that affects ...
Trixeo/Breztri, is approved in the US for treatment of asthma, with regulatory filings currently under review in other major ...
The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than ...
A supplemental New Drug Application (sNDA) for Pfizer’s Talzenna (talazoparib) in combination with Xtandi (enzalutamide) has ...
ELRIG, a not-for-profit, volunteer-led organisation dedicated to the global drug discovery community, has appointed Hitesh ...
Veradermics has announced positive topline results from its open-label phase 2 clinical trial (Study ‘207’) evaluating ...
Almirall’s submission to extend its Marketing Authorisation Application (MAA) for Ebglyss (lebrikizumab) to treat moderate-to ...
AstraZeneca has entered into an exclusive licence agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel ...
How do we translate individual experiences into support that helps others and create support that feels personal but remains ...
Takeda has announced new data from the two pivotal phase 3 studies of zasocitinib (TAK-279) in adults with moderate-to-severe ...
The unique combination of technology marks 25 years of industry innovation and expertise, and signals company’s next phase of ...
Independent network The Bloc has appointed Jon Chapman as European Executive Creative Director. Chapman previously held ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results